Akrevia: Masking immunotherapies en route to tumors

Akrevia is getting around immunotherapy toxicity by masking biologics until they reach tumor microenvironment

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues.

Potent immunotherapies like antibodies, chemokines and cytokines can effectively stimulate the immune system to kill cancer, but because they’re highly immunogenic, they can cause inflammation and toxicity when delivered systemically.

“Really potent biologies which can have a major impact on patient outcomes have not been touchable” due

Read the full 806 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE